Nurix Therapeutics (NRIX) News Today

Nurix Therapeutics, Inc. (NASDAQ: NRIX) is seeing mixed investor sentiment as strong clinical and financial updates are balanced by concerns about execution, partnership dependence and the uncertain commercial outlook for its lead drug, bexobrutideg. Recent analyst targets remain well above the current share price, although the stock is trading below its 50-day moving average.

• Positive Sentiment: Nurix initiated the registrational Phase 3 DAYBreak CLL-306 trial, testing bexobrutideg against pirtobrutinib (JAYPIRCA) in relapsed/refractory CLL/SLL. The trial could support an accelerated approval filing and potentially establish a stronger competitive position for the drug. Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
• Positive Sentiment: Nurix reported third-quarter earnings of $4.73 per share versus the consensus estimate of a $0.56 loss, while revenue of $673.1 million substantially exceeded the approximately $24.4 million forecast. The earnings beat provides near-term financial support, though investors may examine how recurring and sustainable the results are. Nurix Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Analysts remain constructive: Baird raised its price target to $36 with an “outperform” rating, Needham reaffirmed “buy” with a $34 target, and Truist maintained “buy” despite trimming its target to $33. Nurix Therapeutics Q3 2026 Earnings
• Positive Sentiment: A Seeking Alpha analysis maintained a “Strong Buy,” citing bexobrutideg’s pivotal progress, partnership potential and Nurix’s financial resources. Nurix Maintaining Strong Buy
• Neutral Sentiment: RBC Capital Markets said Nurix’s enterprise value remains underappreciated, reinforcing the possibility of valuation upside if clinical and commercial milestones are delivered. Nurix Enterprise Value Remains Underappreciated
• Negative Sentiment: Analysts flagged risks tied to Nurix’s reliance on Roche, including cost burdens, reduced control over development or commercialization and uncertain returns from bexobrutideg. These concerns could limit enthusiasm despite the favorable clinical updates. Nurix’s Reliance on Roche and Bexobrutideg Risks